FDA com­mis­sion­er's vi­sion: Time to re­vamp the ev­i­dence gen­er­a­tion sys­tem

With an eye to­ward fin­ish­ing out Pres­i­dent Biden’s first term in of­fice, FDA com­mis­sion­er Rob Califf said Tues­day af­ter­noon that he’ll seek to ad­dress (on top of the in­fant for­mu­la and food-re­lat­ed fi­as­cos) mis­in­for­ma­tion and cre­at­ing new ways to bol­ster the wider ev­i­dence gen­er­a­tion sys­tem that the agency re­lies on to make ap­proval de­ci­sions.

While re­fer­ring to the FDA as both a “de­ci­sion-mak­ing ma­chine” and “in essence, a ref­er­ee that plays by a set of rules,” Califf made clear that his sec­ond stint as FDA com­mis­sion­er will be fo­cused more on the em­brace of new da­ta, per­haps harken­ing back to his re­cent work with Google’s par­ent com­pa­ny Al­pha­bet, where he led the firm’s health strat­e­gy and pol­i­cy side.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER